LENZ Therapeutics raises $30M from Ridgeback Capital in PIPE at $19/share

LENZ Therapeutics, Inc.

PIPE financing of $30M with Ridgeback Capital at $19.00 per share; expected to close July 17, 2024.
Proceeds to support regulatory and commercial launch activities for LNZ100, a presbyopia eye drop.
NDA submission for LNZ100 planned mid-2024; Phase 3 CLARITY data cited as strong.
Ridgeback Capital founder Dr. Wayne Holman expressed support; shares unregistered with resale registration to be filed.
Existing cash plus PIPE proceeds to fund pre-commercial and potential launch activities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.